



**UNICHEM**  
**LABORATORIES LTD.**

August 9, 2022

**Department of Corporate Services**  
Bombay Stock Exchange Ltd.  
Phiroze Jeejeebhoy Towers  
Dalal Street,  
Mumbai- 400 001

**Mr. Hari K**  
Asst. Vice President - Operations  
National Stock Exchange of India Ltd  
Exchange Plaza, Bandra – Kurla Complex  
Bandra (East), Mumbai – 400 051

**Dear Sir,**

Ref: BSE Scrip Code -506690: NSE Symbol – UNICHEMLAB

**Sub: Outcome of Board Meeting**

We would like to inform you that Board of Directors at its Meeting held today, i.e. Tuesday, August 9, 2022 approved the Unaudited Financial Results (Standalone & Consolidated) for the first quarter ended June 30, 2022. Enclosed herewith please find the Unaudited Financial Results (Standalone & Consolidated) for the first quarter ended June 30, 2022 and the Auditors Reports thereon.

The Board Meeting commenced at 11:15 a.m. and concluded at 1:00 p.m.

Kindly take the same on your records.

Thanking you,  
**FOR UNICHEM LABORATORIES LIMITED**

Pradeep Bhandari  
Head- Legal & Company Secretary

Encl: a/a

**UNICHEM LABORATORIES LIMITED**
**CIN: L99999MH1962PLC012451**
**Statement of Standalone Unaudited Results for the Quarter ended 30th June, 2022**

Particulars	₹ Lakhs			
	Quarter ended 30th Jun'22 (Unaudited)	Quarter ended 31st Mar'22 (Unaudited)	Quarter ended 30th Jun'21 (Unaudited)	Year ended 31st Mar'22 (Audited)
<b>I</b> Revenue from operations	24,478.13	27,686.48	20,080.31	94,292.66
<b>II</b> Other income (Refer note 4)	1,184.53	907.79	1,255.96	4,206.79
<b>III Total income (I+II)</b>	<b>25,662.66</b>	<b>28,594.27</b>	<b>21,336.27</b>	<b>98,499.45</b>
<b>IV EXPENSES</b>				
Cost of materials consumed	12,058.23	11,767.93	10,009.34	43,492.03
Purchase of stock-in-trade	44.95	27.83	38.40	134.90
Changes in inventories of finished goods and work-in-progress	(1,783.41)	(742.20)	(1,840.89)	(5,279.05)
Employee benefits expense	6,706.12	6,304.36	6,309.36	25,079.27
Finance costs	166.66	57.70	13.91	207.42
Impairment loss on financial assets	56.95	113.90	-	806.07
Depreciation and amortization expenses	2,256.97	2,126.80	2,010.65	8,318.76
Other expenses	8,484.10	8,965.51	8,433.80	34,414.82
<b>Total expenses (IV)</b>	<b>27,990.57</b>	<b>28,621.83</b>	<b>24,974.57</b>	<b>1,07,174.22</b>
<b>V Profit / (loss) before exceptional items and tax (III-IV)</b>	<b>(2,327.91)</b>	<b>(27.56)</b>	<b>(3,638.30)</b>	<b>(8,674.77)</b>
<b>VI Exceptional items</b>	-	-	-	-
<b>VII Profit / (loss) before tax (V-VI)</b>	<b>(2,327.91)</b>	<b>(27.56)</b>	<b>(3,638.30)</b>	<b>(8,674.77)</b>
<b>VIII Tax expense</b>				
(1) Current tax	-	-	-	-
(2) Deferred tax charge / (credit) (Refer note 5)	-	(1,760.71)	(879.14)	(3,155.51)
(3) Short / (excess) provision for tax (earlier years)	-	-	23.70	23.70
	-	<b>(1,760.71)</b>	<b>(855.44)</b>	<b>(3,131.81)</b>
<b>IX Profit / (loss) for the period after tax (VII-VIII)</b>	<b>(2,327.91)</b>	<b>1,733.15</b>	<b>(2,782.86)</b>	<b>(5,542.96)</b>
<b>X Other Comprehensive Income / (Loss)</b>				
A. (i) Items that will not be reclassified subsequently to profit or loss				
- Remeasurement of the net defined benefit plan	206.16	(68.82)	(23.60)	(323.91)
- Equity instruments through other comprehensive income	-	7,646.40	-	7,646.40
(ii) Income tax (expense) / credit relating to items that will not be reclassified to profit or loss				
- Remeasurement of the net defined benefit plan	-	-	-	(24.58)
- Equity instruments through other comprehensive income (net)	-	(1,760.71)	-	(1,760.71)
B. (i) Items that will be reclassified to profit or loss	-	-	-	-
(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
<b>Total of Other Comprehensive Income / (Loss)</b>	<b>206.16</b>	<b>5,816.87</b>	<b>(23.60)</b>	<b>5,537.20</b>
<b>XI Total Comprehensive Income for the period (IX+X)</b>	<b>(2,121.75)</b>	<b>7,550.02</b>	<b>(2,806.46)</b>	<b>(5.76)</b>
<b>XII Paid-up equity share capital (Face value of ₹ 2/- per share)</b>	1,408.12	1,408.12	1,408.12	1,408.12
<b>XIII Other Equity (Reserves excluding revaluation reserve)</b>				2,65,795.97
<b>XIV Earnings per equity share (Face value of ₹ 2/- per share) (not annualized)</b>				
(1) Basic	(3.31)	2.46	(3.95)	(7.87)
(2) Diluted	(3.31)	2.46	(3.95)	(7.87)

**Notes:**

- The above unaudited standalone financial results for the quarter ended 30th June, 2022 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on 9th August, 2022. The statutory auditors have carried out a limited review of the standalone financial results for the quarter ended 30th June, 2022.
- The above unaudited standalone financial results have been prepared in accordance with the guidelines issued by the Securities and Exchange Board of India ("SEBI") and the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013.
- Operating Segment: The Company has a single reportable segment i.e. 'Pharmaceuticals'.
- 'Other Income' for the year ended 31st March, 2022 includes dividend income of ₹ 1,000.98 lakhs received on investments in equity shares held by the Company.
- Deferred tax assets is recognised on the amount of tax loss, unabsorbed tax depreciation and other temporary differences to the extent of deferred tax liability.

- 6 On 9th July, 2014, the European Commission ("EU") decided to impose an unjustified fine of Euro 13.96 million, jointly and severally on the Company and its subsidiary Niche Generics Ltd. ("Niche") contending that they had acted in breach of EU competition law as Niche had, in early 2005 (when the Company was only a part owner and financial investor in Niche) had agreed to settle a financially crippling patent litigation with Laboratories Servier. The Company vehemently denies any wrongdoing on the part of either itself or Niche. Both the Company & Niche had submitted appeals in September 2014 to the General Court of the EU seeking appropriate relief in the matter. The General Court of the EU has rejected the appeals vide Order dated 12th December, 2018 and confirmed the fine of Euro 13.96 million. The Company and its subsidiary based on legal advice and merits have filed appeals against the decision of General Court before the Court of Justice of the EU and outcome of the appeals are awaited.

In this regard, the statutory auditors of Niche had given qualified audit opinion on the financial statement of Niche for the year ended 31st March, 2022 and continued the qualification in their limited review report for the quarter ended 30th June, 2022. They had stated that, "previously the outcome of the appeal was sufficiently uncertain that a contingent liability was deemed sufficient, however, following the hearing in October 2021 and their review of the available documentation, their opinion is that it is more likely than not that Niche will be liable for the fine of Euro 13.96 million (equivalent to ₹ 11,526.86 lakhs) and hence, they believe that this should be provided for in the financial statement of Niche. As per the Board of Directors of Niche, there remains an inherent uncertainty as to the outcome of the appeal and therefore, the Directors are of the opinion that no provision should be made at this point of time." The management has obtained the counsel view on this matter and they have stated that there has not been any formal change in position after the last hearing and the uncertainty as in the past continues. Considering the status quo, in view of the management, no provision for the aforesaid fine is considered necessary and the matter is continued to be disclosed under contingent liability.

As at last audited balance sheet date, the Company has aggregate financial exposure of ₹ 12,267.33 lakhs in Niche comprising of investment, trade receivable and corporate guarantee given to bank for loan availed by Niche. Considering the impact of ongoing litigation as elaborated in the above para and accumulated losses in Niche as at balance sheet date, the statutory auditor of the Company is of the view that the Company would need to provide for impairment on the exposure involved of ₹ 12,267.33 lakhs. However, the Company is of the view that such provision for impairment on exposure would be required only in the event of unfavourable outcome of the appeal which itself is uncertain. On the above matter, the auditors of the Company had given qualified opinion in their audit report on standalone financial statement for the year ended 31st March, 2022 and continued the qualification in their limited review report for the quarter ended 30th June, 2022.

Further, as per the management, the future business outlook and projections of the subsidiary are sufficient so as not to warrant any impairment on the investments in subsidiary (Niche) unless the outcome of EU matter is not in favour of the subsidiary.

- 7 During quarter ended 30th June, 2022, the Company has entered into binding Share Purchase Agreement ('SPA') dated 10th May, 2022 with Sekhmet Pharmaventures Private Limited ('Purchaser') and Optimus Drugs Private Limited ('Optimus') to sell its entire shareholding in Optimus to the Purchaser ('Transaction'). As per the SPA, the Company will sell 19.97% equity shares on a fully diluted basis in the first tranche and remaining 0.02% equity shares in the second tranche. For the first tranche, total consideration is ₹ 27,098.99 lakhs and for the second tranche for a price to be determined as per the said SPA after satisfaction of necessary conditions precedent. Fair value gain of ₹ 7,646.40 lakhs is recognised in Other Comprehensive Income in the quarter and year ended 31st March, 2022 based on independent valuation report and carrying value of such investment is ₹ 22,595.23 lakhs. The additional fair value gain will be recognised in the subsequent period as per SPA. The Transaction is expected to complete in the subsequent period after satisfaction of necessary condition precedents as mutually agreed between the parties under the SPA.
- 8 Impairment loss on financial assets for the year ended 31st March, 2022 includes ₹ 569.31 lakhs of provision towards impairment of equity investment in 'Synchron Research Services Private Limited' (associate company).
- 9 During the quarter ended 30th June, 2022, the Company has invested USD 1,87,500 (equivalent to ₹ 146.87 lakhs) towards equity in wholly owned subsidiary - "Unichem (China) Pvt Ltd."
- 10 The aggregate amount of revenue expenditure incurred on Research and Development as included in the relevant expense heads is as tabulated below:

Particulars	₹ Lakhs			
	Quarter ended 30th Jun'22	Quarter ended 31st Mar'22	Quarter ended 30th Jun'21	Year ended 31st Mar' 22
Total R&D expenditure	2,205.28	3,014.73	3,097.70	11,274.10

- 11 The Statement includes unaudited results for the quarter ended 31st March, 2022 being the derived figures between the audited annual figures in respect of the financial year ended 31st March, 2022 and the published unaudited figures for the nine months ended 31st December, 2021, which were subjected to a limited review.

By Order of the Board  
For Unichem Laboratories Limited



Dr. Prakash A. Mody  
Chairman & Managing Director  
DIN: 00001285

Place: Mumbai  
Date: 9th August, 2022

**UNICHEM LABORATORIES LIMITED**
**CIN: L99999MH1962PLC012451**
**Statement of Consolidated Unaudited Results for the Quarter ended 30th June, 2022**

Particulars	₹ Lakhs			
	Quarter ended 30th Jun'22 (Unaudited)	Quarter ended 31st Mar'22 (Unaudited)	Quarter ended 30th Jun'21 (Unaudited)	Year ended 31st Mar'22 (Audited)
<b>I</b> Revenue from operations	30,960.83	36,995.36	29,791.26	1,26,983.22
<b>II</b> Other income (Refer note 4)	784.74	1,439.05	1,580.86	4,750.94
<b>III Total income (I+II)</b>	<b>31,745.57</b>	<b>38,434.41</b>	<b>31,372.12</b>	<b>1,31,734.16</b>
<b>IV EXPENSES</b>				
Cost of materials consumed	12,848.25	12,668.56	10,719.09	45,601.35
Purchase of stock-in-trade	44.95	27.83	38.40	134.90
Changes in inventories of finished goods and work-in-progress	(1,867.23)	(2,864.14)	277.98	(4,153.41)
Employee benefits expense	8,776.75	8,554.23	8,162.34	33,048.96
Finance costs	301.12	158.56	101.35	610.53
Impairment loss on financial assets	56.95	113.91	-	723.89
Depreciation and amortization expenses	2,454.54	2,330.46	2,211.93	9,116.61
Other expenses	11,197.70	11,651.47	10,757.60	44,348.34
<b>Total expenses (IV)</b>	<b>33,813.03</b>	<b>32,640.88</b>	<b>32,268.69</b>	<b>1,29,431.17</b>
<b>V</b> Share of profit / (loss) in associate (net of tax)	-	-	(7.57)	(106.10)
<b>VI Profit / (loss) before exceptional items and tax (III- IV+V)</b>	<b>(2,067.46)</b>	<b>5,793.53</b>	<b>(904.14)</b>	<b>2,196.89</b>
<b>VII</b> Exceptional items	-	-	-	-
<b>VIII Profit / (loss) before tax (VI-VII)</b>	<b>(2,067.46)</b>	<b>5,793.53</b>	<b>(904.14)</b>	<b>2,196.89</b>
<b>IX</b> Tax expense				
(1) Current tax	300.22	547.40	207.82	1,050.83
(2) Deferred tax charge / (credit) (Refer note 5)	(30.81)	(1,901.08)	13.22	(2,183.81)
(3) Short / (excess) provision for tax (earlier years)	-	-	23.70	23.70
	<b>269.41</b>	<b>(1,353.68)</b>	<b>244.74</b>	<b>(1,109.28)</b>
<b>X Profit / (loss) for the period after tax (VIII-IX)</b>	<b>(2,336.87)</b>	<b>7,147.21</b>	<b>(1,148.88)</b>	<b>3,306.17</b>
<b>XI</b> Other Comprehensive Income / (Loss)				
A. (i) Items that will not be reclassified subsequently to profit or loss				
- Remeasurement of the net defined benefit plan	206.16	(68.82)	(23.60)	(323.91)
- Equity instruments through other comprehensive income	-	7,646.40	-	7,646.40
(ii) Income tax (expense) / credit relating to items that will not be reclassified to profit or loss				
- Remeasurement of the net defined benefit plan	-	-	-	(24.58)
- Equity instruments through other comprehensive income (net)	-	(1,760.71)	-	(1,760.71)
B. (i) Items that will be reclassified to profit or loss (Foreign currency translation difference)	479.24	67.90	8.09	(162.15)
(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
<b>Total of Other Comprehensive Income / (Loss)</b>	<b>685.40</b>	<b>5,884.77</b>	<b>(15.51)</b>	<b>5,375.05</b>
<b>XII Total Comprehensive Income for the period (X+XI)</b>	<b>(1,651.47)</b>	<b>13,031.98</b>	<b>(1,164.39)</b>	<b>8,681.22</b>
<b>XIII</b> Paid-up equity share capital (Face value of ₹ 2/- per share)	1,408.12	1,408.12	1,408.12	1,408.12
<b>XIV</b> Other Equity (Reserves excluding revaluation reserve)				2,60,432.98
<b>XV</b> Earnings per equity share (Face value of ₹ 2/- per share) (not annualized)				
(1) Basic	(3.32)	10.15	(1.63)	4.70
(2) Diluted	(3.32)	10.14	(1.63)	4.68

**Notes:**

1 The above unaudited consolidated financial results for the quarter ended 30th June, 2022 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on 9th August, 2022. The statutory auditors have carried out a limited review of the consolidated financial results for the quarter ended 30th June, 2022.

- 2 The above unaudited consolidated financial results have been prepared in accordance with the guidelines issued by the Securities and Exchange Board of India ("SEBI") and the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013.
- 3 Operating Segment: The Company has a single reportable segment i.e. 'Pharmaceuticals'.
- 4 'Other Income' for the year ended 31st March, 2022 includes dividend income of ₹ 1,000.98 lakhs received on investments in equity shares held by the Company.
- 5 In respect of the Company, deferred tax assets is recognised on the amount of tax loss, unabsorbed tax depreciation and other temporary differences to the extent of deferred tax liability.

In respect of a subsidiary, deferred tax assets (net) are recognised as per applicable tax laws.

- 6 On 9th July, 2014, the European Commission ("EU") decided to impose an unjustified fine of Euro 13.96 million, jointly and severally on the Company and its subsidiary Niche Generics Ltd. ("Niche") contending that they had acted in breach of EU competition law as Niche had, in early 2005 (when the Company was only a part owner and financial investor in Niche) had agreed to settle a financially crippling patent litigation with Laboratories Servier. The Company vehemently denies any wrongdoing on the part of either itself or Niche. Both the Company & Niche had submitted appeals in September 2014 to the General Court of the EU seeking appropriate relief in the matter. The General Court of the EU has rejected the appeals vide Order dated 12th December, 2018 and confirmed the fine of Euro 13.96 million. The Company and its subsidiary based on legal advice and merits, have filed appeals against the decision of General Court before the Court of Justice of the EU and outcome of the appeals are awaited. The management has obtained the counsel view on this matter and they have stated that there has not been any formal change in position after the last hearing and the uncertainty as in the past continues. Considering the status quo, in view of the management, no provision for the aforesaid fine is considered necessary and fine imposed by the EU of Euro 13.96 million (equivalent to Rs. 11,526.86 lakhs) is continued to be disclosed under contingent liability.

On the above matter, the auditors of Niche have given qualified conclusion in their limited review report and the statutory auditor of the Company have reported the said qualification in their limited review report on consolidated financial statement for the quarter ended 30th June, 2022. The above matter was also qualified in the audit reports issued by Niche auditor and statutory auditor of the Company for the previous year ended 31st March, 2022.

- 7 During quarter ended 30th June, 2022, the Company has entered into binding Share Purchase Agreement ('SPA') dated 10th May, 2022 with Sekhmet Pharmaventures Private Limited ('Purchaser') and Optimus Drugs Private Limited ('Optimus') to sell its entire shareholding in Optimus to the Purchaser ('Transaction'). As per the SPA, the Company will sell 19.97% equity shares on a fully diluted basis in the first tranche and remaining 0.02% equity shares in the second tranche. For the first tranche, total consideration is ₹ 27,098.99 lakhs and for the second tranche for a price to be determined as per the said SPA after satisfaction of necessary conditions precedent. Fair value gain of ₹ 7,646.40 lakhs is recognised in Other Comprehensive Income in the quarter and year ended 31st March, 2022 based on independent valuation report and carrying value of such investment is ₹ 22,595.23 lakhs. The additional fair value gain will be recognised in the subsequent period as per SPA. The Transaction is expected to complete in the subsequent period after satisfaction of necessary condition precedents as mutually agreed between the parties under the SPA.
- 8 Impairment loss on financial assets for the year ended 31st March, 2022 includes ₹ 569.31 lakhs of provision towards impairment of equity investment in 'Synchron Research Services Private Limited' (associate company).
- 9 The aggregate amount of revenue expenditure incurred on Research and Development as included in the relevant expense heads is as tabulated below:

₹ Lakhs

Particulars	Quarter ended 30th Jun'22	Quarter ended 31st Mar'22	Quarter ended 30th Jun'21	Year ended 31st Mar' 22
Total R&D expenditure	2,205.28	3,014.73	3,097.70	11,274.10

- 10 The Statement includes unaudited results for the quarter ended 31st March, 2022 being the derived figures between the audited annual figures in respect of the financial year ended 31st March, 2022 and the published unaudited figures for the nine-months ended 31st December, 2021, which were subjected to a limited review.

By Order of the Board  
For Unichem Laboratories Limited



Dr. Prakash A. Mody  
Chairman & Managing Director  
DIN: 00001285

Place: Mumbai  
Date: 9th August, 2022

**Limited Review Report on quarterly standalone unaudited financial results of Unichem Laboratories Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

**To**  
**The Board of Directors**  
**Unichem Laboratories Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results ("the Statement") of **Unichem Laboratories Limited** ("the Company") for the quarter ended 30<sup>th</sup> June, 2022, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

**Management's responsibility**

2. The Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.

The Statement includes unaudited results for the quarter ended 31<sup>st</sup> March, 2022, being the derived figures between the unaudited annual figures in respect of the financial year ended 31<sup>st</sup> March, 2022 and the published unaudited figures for the nine months ended 31<sup>st</sup> December, 2021, which were subjected to a limited review.

**Auditor's responsibility**

3. Our responsibility is to issue a report on this Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus, provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

**Limited Review Report on quarterly standalone unaudited financial results of Unichem Laboratories Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (continued...)**

**Basis for qualified conclusion**

4. We draw attention to note 6 of the Statement regarding the EU fine matter and the Company's financial exposure as on the last audited balance sheet date of Rs. 12,267.33 lakhs in the subsidiary (Niche Generics Limited, UK) in respect of which, in our view, the Company would need to provide for impairment of the exposure of Rs. 12,267.33 lakhs. However, the Company is of the view that such provision for impairment on exposure would be required only in the event of unfavourable outcome of the appeal which itself is uncertain. Our conclusion is modified in respect of this matter for the quarter ended 30<sup>th</sup> June, 2022 and our opinion was also modified for the aforesaid matter in the year ended 31<sup>st</sup> March, 2022.

**Qualified conclusion**

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, except for the effects of the matter described in 'Basis for qualified conclusion' paragraph above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited financial results, prepared in accordance with recognition and measurement principles laid down in the applicable Indian Accounting Standards i.e. "Ind AS" prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For N. A. Shah Associates LLP**

Chartered Accountants

Firm's Registration No.: 116560W / W100149

MILAN NAVIN Digitally signed by MILAN  
NAVIN MODY  
MODY Date: 2022.08.09 13:01:42  
+05'30'

**Milan Mody**

Partner

Membership No.: 103286

UDIN: 22103286AOPHGB7224

Place: Mumbai

Date: 9<sup>th</sup> August, 2022



  
**N. A. SHAH ASSOCIATES LLP**  
Chartered Accountants

**Limited Review Report on quarterly unaudited consolidated financial results of Unichem Laboratories Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

**To**  
**The Board of Directors**  
**Unichem Laboratories Limited**

1. We have reviewed the accompanying statement of unaudited consolidated financial results of **Unichem Laboratories Limited** (“the Holding Company”), comprising its subsidiaries (the Holding and its subsidiaries collectively referred to as “the Group”) and its share of the net loss after tax and total comprehensive income of its associate for the quarter ended 30<sup>th</sup> June, 2022 (“the Statement”), being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“Listing Regulations”).

**Management’s responsibility**

2. The Statement is the responsibility of the Holding Company's Management and has been approved by the Holding Company's Board of Directors. The Statement has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “Interim Financial Reporting” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India.

The Statement includes unaudited results for the quarter ended 31<sup>st</sup> March, 2022 being the derived figures between the audited annual figures in respect of the financial year ended 31<sup>st</sup> March, 2022 and the published unaudited figures for the nine months ended 31<sup>st</sup> December, 2021 which were subjected to a limited review.

**Auditor’s responsibility**

3. Our responsibility is to issue a report on this Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.



  
**N. A. SHAH ASSOCIATES LLP**  
Chartered Accountants

**Limited Review Report on quarterly unaudited consolidated financial results of Unichem Laboratories Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (continued...)**

4. These unaudited consolidated financial results:

(a) include results of the following subsidiaries:

- i. Niche Generics Limited, United Kingdom
- ii. Unichem Pharmaceuticals (USA), Inc., USA
- iii. Unichem Laboratories Limited, Ireland
- iv. Unichem SA (Pty) Limited, South Africa
- v. Unichem Farmaceutica Do Brasil Ltda, Brazil
- vi. Unichem (China) Pvt. Ltd.

(b) include results of the associate: Synchron Research Services Pvt. Ltd.

**Basis for qualified conclusion**

5. We draw attention to note 6 of the Statement which sets out the current ongoing litigation regarding the EU matter that the subsidiary (Niche Generics Limited, UK) is facing. The auditors of Niche have issued a qualified conclusion for the quarter ended 30<sup>th</sup> June, 2022 stating that:

“Niche Generics Limited has not recognized a provision on account of an ongoing appeal against a fine imposed by the European Commission. Whilst previously the outcome of the appeal was sufficiently uncertain that a contingent liability was deemed sufficient, following the hearing in October 2021 and our review of the available documentation, our opinion is that it is more likely than not that the Company will be liable for the fine of Euro 13.96 million (worth approximately GBP 11.8 million at the balance sheet date). Accordingly, we believe that this should have been provided for in the financial statement for the year ended 31<sup>st</sup> March, 2022. The Directors’ opinion is that there remains an inherent uncertainty as to the outcome of the appeal and therefore, the Directors are of the opinion that no provision should be made at this point in time. The impact on these financial statements of including the provision would be that the Company would have net liabilities of approximately GBP 11.9 million at the balance sheet date.”

Our conclusion is modified in respect of this matter for the quarter ended 30<sup>th</sup> June, 2022 and our opinion was also modified for the aforesaid matter in the year ended 31<sup>st</sup> March, 2022.

**Qualified conclusion**

6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 7 below, except for the effects of the matter described in ‘Basis for qualified conclusion’ paragraph above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

  
**N. A. SHAH ASSOCIATES LLP**  
Chartered Accountants

**Limited Review Report on quarterly and year to date unaudited consolidated financial results of Unichem Laboratories Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (continued...)**

**Other matters**

7. We did not review the interim financial statements of five subsidiaries, whose interim financial statements reflect total revenues (including other income) of Rs. 20,515.92 lakhs, total net profit after tax and total comprehensive income of Rs. 300.70 lakhs for the quarter ended 30<sup>th</sup> June, 2022 as considered in the unaudited consolidated financial results. These financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the unaudited consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and our report in terms of the Listing Regulations (as amended), in so far as it relates to aforesaid subsidiaries located outside India is based on the report of other auditors.
8. We also did not review the interim financial information of subsidiary at China whose financial information reflect total net profit / (loss) after tax and total comprehensive income of Rs. (45.31) lakhs for the quarter ended 30<sup>th</sup> June, 2022 as considered in the unaudited consolidated financial results. This financial information is not subject to limited review and have been furnished to us by the Management and our conclusion on the unaudited consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of this subsidiary is solely based on the information provided by the Management. According to the information and explanations given to us by the Management, this financial information is not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matters.

**For N. A. Shah Associates LLP**

Chartered Accountants

Firm's Registration No.: 116560W / W100149

MILAN  
NAVIN  
MODY

Digitally signed by N. A. SHAH ASSOCIATES LLP  
DN: cn=N. A. Shah Associates LLP, o=N. A. Shah Associates LLP, ou=N. A. Shah Associates LLP, email=N.A.SHAH@NASHAASSOCIATESLLP.COM, c=IN  
Date: 2022.08.09 18:02:59 +05'30'

**Milan Mody**

Partner

Membership No.: 103286

UDIN: 22103286AOPIGI5269

Place: Mumbai

Date: 9<sup>th</sup> August, 2022